Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns

Pediatric Infectious Disease Journal

Volumn 23, Issue 4, 2004, Pages 361-363

  Leineweber, Birgit ^a,c   Grote, Veit ^b   Schaad, Urs B ^a   Heininger, Ulrich ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antibodies; Enzyme linked immunosorbent assay; Maternally acquired immunity; Measles; Mumps; Premature infant; Rubella; Varicella

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY;

ANTIBODY DETECTION; ARTICLE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES VIRUS; MUMPS VIRUS; NEWBORN; NONHUMAN; PLACENTAL TRANSFER; PREMATURITY; PRIORITY JOURNAL; RUBELLA VIRUS; UMBILICAL CORD BLOOD; VARICELLA ZOSTER VIRUS;

ADULT; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MATERNAL-FETAL EXCHANGE; MEASLES VIRUS; MUMPS VIRUS; PREGNANCY; RISK ASSESSMENT; RUBELLA VIRUS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 1942420276     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200404000-00019     Document Type: Article

References (11)

1. Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996;97:53-8.
2. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996;36:248-55.
3. Linder N, Sirota L, Aboudy Y, et al. Placental transfer of maternal rubella antibodies to full-term and preterm infants. Infection 1999;27:203-7.
4. Linder N, Waintraub I, Smetana Z, et al. Placental transfer and decay of varicella-zoster virus antibodies in preterm infants. J Pediatr 2000;137:85-9.
5. Desgrandchamps D, Schaad UB, Glaus J, Tusch G, Heininger U. Seroprevalence of IgG antibodies against measles, mumps and rubella in Swiss children during the first 16 months of life. Schweiz Med Wochenschr 2000;130:1479-86.
6. Schwarzer S, Reibel S, Lang AB, et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 1998;16:298-304.
7. Evans HE, Akpata SO, Glass L. Serum immunoglobulin levels in premature and full-term infants. Am J Clin Pathol 1971;56:416-8.
8. van der Zwet WC, Vandenbroucke-Grauls CM, van Elburg RM, Cranendonk A, Zaaijer HL. Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight, and maternal titer. Pediatrics 2002;109:79-85.
9. Mendez DB, Sinclair MB, Garcia S, Chou T, Meadow W. Transplacental immunity to varicella-zoster virus in extremely low birthweight infants. Am J Perinatol 1992;9: 236-8.
10. Klinge J, Lugauer S, Korn K, Heininger U, Stehr K. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000;18:3134-40.
11. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001;184:817-26.